Royal Bank of Canada reiterated their sector perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $21.00 price objective on the stock, up from their previous price objective of $16.00. FUSN has been the topic of several other research […]
SVB Leerink reaffirmed their market perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the stock, up from their prior target price of $17.00. Several other equities analysts have also commented on […]
William Blair cut shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) from an outperform rating to a market perform rating in a report published on Tuesday, MarketBeat.com reports. William Blair also issued estimates for Fusion Pharmaceuticals’ Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.47) EPS and […]
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […]
Forefront Analytics LLC grew its position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) by 67.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 33,685 shares of the company’s stock after buying an additional 13,610 shares during the period. Forefront Analytics LLC’s holdings in […]